RxDoctor Payments Data

Jason Fishbein, MD

Internal Medicine · Bethpage, NYNPI 1972602555

Payments from drug & device makers

$3,828in general payments, 2019–2025

Across 214 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$393
  • Novo Nordisk$316
  • Merck$263
  • Boehringer Ingelheim$262
  • Novartis$248
  • Medtronic$211
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$3,828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,828 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$196,930
Medicare patients
356
Services billed
3,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin52$86,564
JanuviaSitagliptin Phosphate27$41,676
OzempicSemaglutide13$32,030
EliquisApixaban28$31,525
TrulicityDulaglutide20$30,757
FarxigaDapagliflozin Propanediol19$29,110
XareltoRivaroxaban27$28,324
EntrestoSacubitril/Valsartan14$18,356
MounjaroTirzepatide11$11,041
Rosuvastatin Calcium420$4,730
VascepaIcosapent Ethyl13$4,492
SynthroidLevothyroxine Sodium66$4,020
Atorvastatin Calcium428$3,473
Levothyroxine Sodium213$2,965
Valsartan97$2,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$262$86,56452 claims
Lilly USA, LLCTrulicity, Mounjaro$393$41,79831 claims
MerckJanuvia$263$41,67627 claims
Novo NordiskOzempic$316$32,03013 claims
PfizerEliquis$143$31,52528 claims
AstraZenecaFarxiga$51$29,11019 claims
Johnson & JohnsonXarelto$83$28,32427 claims
NovartisEntresto$248$18,35614 claims
AbbVieSynthroid$55$4,02066 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$113$2,965213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bethpage

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →